First, it is well known that actionable mutations, such as epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK), lead to unregulated proliferation and survival of tumor cells and associated with advanced NSCLC stages. This evidence concerns the gene EGFR and non-small cell lung carcinoma.